Wet AMD – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Wet AMD

Wet AMD – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Wet Age-related macular degeneration  AMD, or advanced neovascular AMD, is a serious type of AMD that happens when a protein called vascular endothelial growth factor (VEGF) makes too many blood vessels grow in the back of your eye. These blood vessels can damage a part of your eye called the macula, leading to central vision loss. Wet AMD is caused by new blood vessels leaking fluid into the retina. This causes the retina to become “wet.” Initially, the fluid causes reversible vision loss, but the vision loss can become permanent within weeks to months, if untreated.

According to Thelansis, The wet/neovascular type affects approximately 10-15% of individuals with age-related macular degeneration, but accounts for approximately 90% of all cases of severe vision loss from the disease.

Competitive landscape of Wet AMD includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Wet AMD across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Wet AMD Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Wet AMD – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

S. No        Asset        Company                                             Phase

1        Ranibizumab        Samsung Bioepis Co., Ltd.                      III

2        APL-2                Apellis Pharmaceuticals, Inc. (APLS)        I/II

3        Conbercept        Chengdu Kanghong Biotech Co.,Ltd.        III

4        FYB201                Santo Holding GMBH                                III

5        ONS-5010        Outlook Therapeutics, Inc. (OTLK)                III

6        GB-102                GrayBug, Inc.                                                IIb

7        OPT-302                Opthea Limited (ASX: OPT)                        IIb

8        AKST4290        Alkahest, Inc.                                                II

9        HCB1019        OcuNexus Therapeutics, Inc.                        II

10      ICON-1                Iconic Therapeutics, Inc.                                II